ReNeuron Group said it had recorded positive results from a clinical trial of a treatment for the blindness-causing disease retinitis pigmentosa. All three subjects in the first cohort of a Phase 2a element of the study demonstrated a sustained and further improvement in vision compared with their pre-treatment baseline, the company said. The latest results were being presented on Friday at the Retinal Cell and Gene Therapy Innovation Summit in Vancouver, Canada. 'The extent of vision improvement observed in this patient cohort demonstrates the potential for our hRPC cell therapy candidate to make an enormous difference in the lives of patients with RP,' chief executive Olav Hellebo said. 'Treatment has already begun in the next cohort of patients, who have a greater baseline level of visual acuity than those treated so far.' 'The results from this cohort will be presented in due course.' At 8:26am: (LON:RENE) ReNeuron Group PLC share price was +34p at 296p